Every Form 4 that Artivion, Inc. (AORT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AORT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AORT filings page.
Artivion, Inc. (AORT) insider transaction: SVP and General Counsel Jean F. Holloway reported the sale of 5,761 shares of common stock at $45.858 on 11/13/2025. The filing states the shares were sold upon the vesting of restricted stock units to pay tax withholding obligations via a “sell to cover” and “does not represent a discretionary transaction.”
Following the sale, the reporting person beneficially owns 163,408 shares directly. This Form 4 reflects an administrative tax-related sale rather than an open‑market discretionary trade.
Artivion (AORT) insider transaction: Officer Marshall Stanton reported a sell-to-cover of 4,993 shares of common stock at $45.858 on 11/13/2025. The filing states the shares were sold upon RSU vesting to satisfy tax withholding obligations and did not represent a discretionary transaction.
Following the transaction, Stanton beneficially owns 56,641 shares directly. His role is listed as SVP, Clinical & MD Affair, and the filing was made by one reporting person.
Artivion (AORT) insider activity: The company’s SVP and General Counsel reported multiple transactions. On 11/10/2025, 2,960 shares of common stock were sold at $44.619 to cover tax withholding upon RSU vesting. On 11/11/2025, the insider exercised 10,000 stock options at an exercise price of $11.03 (code M) and sold 10,000 shares at $46.18. Following these transactions, the insider directly held 169,169 common shares.
The option exercised was originally granted with vesting at 33 1/3% per year beginning on 11/08/2023 and had an expiration date of 11/08/2029.
Artivion (AORT) reported an insider transaction by President & CEO James P. Mackin.
On 11/10/2025, 17,580 shares of common stock were sold at $44.619 in a sell-to-cover tied to RSU vesting to satisfy tax withholding; the filing states this was not a discretionary trade.
After the transaction, he directly beneficially owned 835,203 shares.
Artivion, Inc. (AORT) reported an insider transaction. Chief Commercial Officer John E. Davis disclosed the sale of 3,373 shares of common stock on 11/10/2025 at $44.619 per share.
The filing states the shares were sold upon RSU vesting to cover tax withholding obligations via a sell-to-cover and “does not represent a discretionary transaction.” Following the transaction, Davis directly beneficially owned 205,405 shares.
Artivion, Inc. (AORT) insider transaction: the VP, Chief Accounting Officer reported a sale of 1,789 shares of common stock on 11/10/2025 at $44.619 per share. Following the transaction, the reporting person beneficially owns 144,862 shares, held directly.
The filing states the shares were sold to cover taxes due upon the vesting of restricted stock units, described as a “sell to cover” and not a discretionary trade.
Artivion, Inc. (AORT) disclosed an insider transaction by its SVP, Clinical & MD Affairs. On 11/10/2025, the officer sold 2,566 shares of common stock at $44.619 per share. The filing states the shares were sold upon the vesting of restricted stock units to cover tax withholding, described as a “sell to cover” and not a discretionary trade.
Following the transaction, the officer directly beneficially owned 61,634 shares. The report was filed as a single‑person Form 4 submission.